SecBot SecBot
8-K ·Filed Jul 20, 2026

RMTI

ROCKWELL MEDICAL, INC.
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago SEC0001628280-26-048752
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

The delisting risk is resolved, which removes a near-term catalyst for forced selling or volatility. However, the stock remains near the $1 threshold, and the company's underlying business fundamentals are unchanged. Monitor next quarterly results for revenue and cash flow trends to assess sustainable listing compliance.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
RMTI ▲ +24.70% at T+60d
NEUTRAL call +24.70% · α vs SPY +19.86% · entry $6.30 → $7.85
Entry = T+0 close
Jul 20, 2026
via day close
T+1d
-0.16%
call -0.16% · α -0.99%
$6.29
settled 3mo ago
T+5d
+5.32%
call +5.32% · α +5.75%
$6.63
settled 3mo ago
T+20d
+18.90%
call +18.90% · α +14.78%
$7.49
settled 2mo ago
T+60d
+24.70%
call +24.70% · α +19.86%
$7.85
settled 15d ago

Price Chart

Loading chart...

Executive Summary

Rockwell Medical announced it has regained compliance with Nasdaq's minimum bid price requirement (Rule 5550(a)(2)) after its stock closed at $1.00 or higher for 10 consecutive trading days from July 1 to July 15, 2026. Nasdaq has closed the matter, and the company is now in full compliance with all continued listing requirements, removing the immediate delisting risk.

Key Facts

  • Received Nasdaq notice on July 16, 2026 confirming compliance with minimum bid price rule
  • Shares maintained closing bid price ≥ $1.00 from July 1 to July 15, 2026
  • Nasdaq has closed the compliance matter
  • Company now in full compliance with all Nasdaq continued listing requirements

Financial Impact

No direct financial impact; removal of delisting risk removes a potential overhang but no financial figures disclosed

Risk Factors

  • Stock price could again fall below $1.00, triggering a new bid price deficiency
  • No improvement in operating performance or revenue growth was disclosed

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-048752
Document: 0001628280-26-048752-index-headers.html0001628280-26-048752
Document: 0001628280-26-048752-index.html0001628280-26-048752
Document: 0001628280-26-048752.txt0001628280-26-048752
5 reports for RMTI
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for RMTI — sortable, filterable
TypeNow
Aug 13, 2026
10w ago
8-K
NEUTRAL ★ 2/10
$7.83awaiting T+60—$6.86 (−12.33%)
Jul 20, 2026
14w ago
8-K
NEUTRAL ★ 2/10
$6.30 $7.85▲ +24.70%▲ +19.86%$6.86 (+8.98%)
Jun 29, 2026
17w ago
8-K
NEUTRAL ★ 2/10
$0.5874 $0.8570▲ +45.90%▲ +42.28%$6.86 (+1067.86%)
May 8, 2026
24w ago
8-K
BEARISH ★ 7/10
$8.40 $7.26▲ +13.57%▲ +17.96%$6.86 (+18.33%)
May 7, 2026
24w ago
8-K
NEUTRAL ★ 2/10
$7.80 $7.23▼ −7.31%▼ −11.14%$6.86 (−12.05%)
Showing 5 of 5

US Market Status

Market Closed — Opens Thu (11h 51m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 20, 2026